These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23518349)

  • 1. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence.
    Takeishi S; Matsumoto A; Onoyama I; Naka K; Hirao A; Nakayama KI
    Cancer Cell; 2013 Mar; 23(3):347-61. PubMed ID: 23518349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.
    Hurtz C; Hatzi K; Cerchietti L; Braig M; Park E; Kim YM; Herzog S; Ramezani-Rad P; Jumaa H; Müller MC; Hofmann WK; Hochhaus A; Ye BH; Agarwal A; Druker BJ; Shah NP; Melnick AM; Müschen M
    J Exp Med; 2011 Oct; 208(11):2163-74. PubMed ID: 21911423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia.
    Naka K; Hoshii T; Muraguchi T; Tadokoro Y; Ooshio T; Kondo Y; Nakao S; Motoyama N; Hirao A
    Nature; 2010 Feb; 463(7281):676-80. PubMed ID: 20130650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
    Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression.
    Reavie L; Buckley SM; Loizou E; Takeishi S; Aranda-Orgilles B; Ndiaye-Lobry D; Abdel-Wahab O; Ibrahim S; Nakayama KI; Aifantis I
    Cancer Cell; 2013 Mar; 23(3):362-75. PubMed ID: 23518350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
    Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
    Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells.
    Wu S; Zheng C; Chen S; Lin B; Chen Y; Zhou W; Li Z
    Biochem Biophys Res Commun; 2015 Jan; 456(1):367-72. PubMed ID: 25475722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
    Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The implication of cancer progenitor cells and the role of epigenetics in the development of novel therapeutic strategies for chronic myeloid leukemia.
    Tortorella SM; Hung A; Karagiannis TC
    Antioxid Redox Signal; 2015 Jun; 22(16):1425-62. PubMed ID: 25366930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
    Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
    Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
    Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
    Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
    Zhao F; Mancuso A; Bui TV; Tong X; Gruber JJ; Swider CR; Sanchez PV; Lum JJ; Sayed N; Melo JV; Perl AE; Carroll M; Tuttle SW; Thompson CB
    Oncogene; 2010 May; 29(20):2962-72. PubMed ID: 20228846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opposing functions of Fbxw7 in keratinocyte growth, differentiation and skin tumorigenesis mediated through negative regulation of c-Myc and Notch.
    Ishikawa Y; Hosogane M; Okuyama R; Aoyama S; Onoyama I; Nakayama KI; Nakayama K
    Oncogene; 2013 Apr; 32(15):1921-32. PubMed ID: 22665065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.
    Albajar M; Gómez-Casares MT; Llorca J; Mauleon I; Vaqué JP; Acosta JC; Bermúdez A; Donato N; Delgado MD; León J
    Mol Cancer Res; 2011 May; 9(5):564-76. PubMed ID: 21460180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
    Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
    Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells.
    Burthem J; Rees-Unwin K; Mottram R; Adams J; Lucas GS; Spooncer E; Whetton AD
    Leukemia; 2007 Aug; 21(8):1708-14. PubMed ID: 17554385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.
    Moser O; Krumbholz M; Thiede C; Tauer JT; Janz I; Lauten M; Dilloo D; Metzler M; Suttorp M
    Pediatr Blood Cancer; 2014 Nov; 61(11):2080-2. PubMed ID: 24810322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
    Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
    Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.